Business Wire

With Intelligence Announces That Motive Partners Has Acquired a Majority Stake

Share

With Intelligence, a leading provider of investment data and intelligence for allocating, fund-raising and business development in the public and private markets, announced that it has received a majority investment from funds advised by Motive Partners (“Motive”), a specialist private equity firm focused on financial technology. Intermediate Capital Group ("ICG"), who originally invested in With Intelligence in 2020, will invest further alongside Motive. The investment is intended to serve as an accelerant for With Intelligence's growth, as the platform focuses on delivering leading connectivity, data and insights solutions to the Limited Partner and General Partner communities.

Founded in 1998, With Intelligence is a leading provider of data, intelligence and connectivity to the global asset management industry, with an integrated product suite of data, insights and events covering hedge funds, private credit, private equity, real estate and traditional asset management. Established 25 years ago, with over 500 employees and a geographic footprint across Europe, North America and Asia, With Intelligence has seen significant growth in recent years, with over 2,500 customers and a revenue compound annual growth rate of 33%.

With Intelligence blends data from a variety of the platform’s proprietary brands, delivering insights that include profiles, fund information, performance metrics and analyst perspectives. As the alternative investment landscape continues to evolve, With Intelligence is positioned to provide solutions that support mission-critical decision making across the fundraising and allocation lifecycle, for all participants in the value-chain. With Intelligence's strong growth is bolstered by a leading position in the hedge fund market, and is beginning to benefit from significant tailwinds driving the growth of private markets towards an estimated $15 trillion of assets under management in 2027.

Charlie Kerr, Founder & CEO at With Intelligence commented: “There is a huge opportunity for us to serve the global asset management industry during an exciting period of growth with greater data and analytics solutions than presently exist in the market. In order to capitalise on these tailwinds, we have chosen to partner with Motive Partners, who have a strong depth of expertise in financial technology across their group of Investors, Operators and Innovators. I am also grateful to ICG for their continued support and investment in the next phase of our growth journey.”

Neil Cochrane, Partner at Motive Partners commented: “We are positioned at the intersection of two exciting trends - the increase of allocations towards alternatives and the emergence of exciting new analytics and AI technologies to derive insights within the sector. Through the Motive IOI model and our extensive network, we are looking forward to capitalising on this market opportunity in partnership with Charlie, the With Intelligence team, and ICG.”

The investment by Motive and ICG will support With Intelligence to accelerate its data strategy and technology capabilities, continue to develop tailored offerings across various asset classes, grow the private markets offerings, and execute the next phase of the partnership and M&A strategies. It will also enable the company to further accelerate the pace of talent acquisition. Additionally, Motive's integrated operating model ("IOI model"), combining Investors, Operators and Innovators, will see a number of Motive team members collaborate with the With Intelligence team, including Charles Teschner (Industry Partner at Motive and the former CEO of Data and Analytics Solutions at BNY Mellon), Andy Stewart (Industry Partner at Motive, current CEO of Wilshire, and the former Co-Head of Blackrock's Alternative Investment Platform) and a team from Motive's innovation division, Motive Create.

“It has been a privilege to support the With Intelligence management team on their outstanding journey over the past few years, working alongside a visionary and entrepreneurial founder such as Charlie" said Jamie Rivers, Managing Director at ICG. Gareth Knight, Head of European Mid-Market at ICG added: "The company has a proven strategy for growth, and we're delighted to support the business for a further Investment cycle. We see Motive Partners being extremely well placed to help accelerate this over the coming years.”

Global investment banking firm Houlihan Lokey served as financial advisor to With Intelligence on the transaction, with other advisors including Proskauer (Legal), Financial & Tax (Alvarez & Marsal) and OC&C (Commercial). Arrowpoint Advisory, Joelson and Blick Rothenberg supported Management. Motive Partners' financial advisor was Raymond James, and they were also advised by MDW Capital Advisory (Debt Advisor), White & Case (Legal), Plural Strategy, Oliver Wyman (Commercial), and EY (Financial & Tax).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

With Intelligence
Louise Green, Chief Marketing Officer
louise.green@withintelligence.com

Motive Partners
Sam Tidswell-Norrish, Managing Director
sam@motivepartners.com

ICG
Clare Glynn, Head of Corporate Communications
clare.glynn@icgam.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

FieldBee Vision wins Gold for Digital Technology Innovation at LAMMA 20269.1.2026 06:25:00 EET | Press release

FieldBee, the European leader in high-quality, easy-to-use and affordable precision agriculture technologies, proudly announces that FieldBee Vision has earned global recognition, becoming the Gold Winner in the Digital Technology Innovation of the Year category at the LAMMA Innovation Awards 2026. Lamma Show is the UK’s premier agricultural machinery, technology and equipment innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107606411/en/ FieldBee wins the LAMMA Innovation Award 2026 for Digital Technology Innovation of the Year for the FieldBee Vision (VisionSteer & VisionPro) system FieldBee Vision is part of the newly launched myFieldBee ecosystem, built to unify FieldBee’s precision farming tools and designed to connect navigation, autosteering, ISOBUS into one unified platform that supports planning, execution, monitoring and reporting. FieldBee Vision, the first modular retrofit agricultural vision system,

Survey Finds Over 70% of Chinese Doctors Recommend “AI Doctor Services” Like Ant Group’s AQ for Everyday Health Needs9.1.2026 05:31:00 EET | Press release

A recent survey by Life Times, a well-known Chinese public health media outlet, shows that AI doctor services are broadly supported by doctors in China. Among 500 physicians from the country’s top-tier (tertiary) hospitals, more than 70% said they would recommend AI doctor services to patients for everyday health questions and routine health management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108456917/en/ Ant Group’s AI-native health app AQ is designed to address common, everyday health concerns and support healthy habit formation. Ant Group’s AQ was the most frequently recommended platform in the survey. The latest figures show that, as of January 2026, the app had accumulated 30 million monthly active users and answers over 10 million health-related questions daily, making it China’s leading AI-native health app. AQ—known in Chinese as Ant A-Fu—is an AI-native health app launched by Ant Group in June 2025. Desig

OPPO Joins VVC Advance Patent Pool as a Licensee and Extends HEVC Advance License9.1.2026 04:00:00 EET | Press release

Access Advance LLC and Guangdong OPPO Mobile Telecommunications Corp., Ltd. (OPPO) today announced that OPPO has joined the VVC Advance Patent Pool as a Licensee and renewed its HEVC Advance License. OPPO, one of the world's largest smartphone manufacturers with operations in more than 70 countries, has been a valued participant in Access Advance's HEVC patent pool since 2020, and more recently joined the Advance Video Distribution Patent (VDP) Pool as a Licensor. These latest agreements mark a new milestone in a broad and deepening relationship between the two companies, with OPPO now participating across all three of Access Advance's video codec licensing programs. The VVC Advance Patent Pool licenses patents essential to the VVC/H.266 standard, which delivers remarkable improvement of video compression performance over HEVC, enabling higher-quality video experiences including 4K, 8K, and HDR content with faster downloads and lower latency. The pool currently includes over 4,500 worl

Cessna Citation CJ3 Gen2 Enters Into Service, Delivering the Most Significant Gen2 Updates to Date8.1.2026 23:30:00 EET | Press release

The Cessna Citation CJ3 Gen2 has entered into service, setting a new standard for the Citation Gen2 family. Launch customers and longtime Citation owners Dave Mecartney and Shannon Day took delivery of their new aircraft this week. Mecartney—an experienced aviator with nearly two decades flying Citation light jets and a member of Textron Aviation’s Customer Advisory Board—helped shape the enhancements that elevate the CJ3 Gen2 experience. Key upgrades include Garmin autothrottle technology, added pilot legroom and a fully customizable cabin environment, all driven by customer feedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108455097/en/ Cessna Citation CJ3 Gen2 enters into service, delivering the most significant Gen2 updates to date (Photo credit: Textron Aviation). The Cessna Citation CJ3 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The Citation CJ3 Gen2 deliv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye